Figure 4.
AR-42 and MS-275 Enhance the NIS Promoter Activity and Expression In Vivo
(A) Bioluminescence (BLI) images of representative mouse with orthotopic ZR-75-1 NF tumors showing change in NIS promoter activity in untreated control and AR-42 drug-treated groups. (B) Graph showing BLI signal quantified from control and treated groups, normalized to the respective signals before treatment. Error bar indicates SEM (n = 2).∗p ≤ 0.05 calculated by Student’s t test. (C and D) BLI images of representative mouse, AR-42- or MS-275-treated groups, respectively, along with untreated control. Color scale bar indicates photon signal strength (photon/s/cm2/sr). (E and F) Graph showing quantified BLI signal from control and treated mice before and after AR-42 or MS-275 treatment, respectively. Error bar indicates SEM (n = 3). (G and H) Photomicrographs of NIS IHC performed on control and (G) AR-42- or (H) MS-275-treated tumors as marked. DAB staining (brown) and respective hematoxylin and eosin (H&E)-stained images are displayed.